Cell>Point

Cell>Point's cornerstone is metabolic imaging and therapeutic targeting through intranuclear chelation technology. The company is developing universal molecular imaging agents for oncology, cardiology, stroke, and diabetes, as well as intranuclear metal therapies. Cell>Point is a privately-held biotechnology company with offices in Centennial, Colorado, Houston, and Saratoga, California. The company’s five technology platforms—Ethylenecysteine Drug Conjugate Technology (“EC Technology”), In-Situ Hydrogel (“In-Situ Hydrogel Technology”), Tetraazacyclododecane Technology (“N4 Technology”), Oligosaccharide Conjugate Technology (“Dual-Agent Technology”), and Mechanism-Based Targeting of Pancreatic Beta Cells Technology (“Beta-Cell Technology”)—are being developed to create new radiodiagnostic imaging agents and new intranuclear therapeutic agents.